BIOGEN INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BIOGEN INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.89B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $9.68B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $9.84B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $10.17B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $10.98B | Feb 14, 2024 |
| FY2020 | Dec 31, 2020 | $2.85B | Feb 3, 2021 |
| FY2020 | Sep 30, 2020 | $3.38B | Feb 3, 2021 |
| FY2020 | Jun 30, 2020 | $3.68B | Feb 3, 2021 |
| FY2020 | Mar 31, 2020 | $3.53B | Feb 3, 2021 |
| FY2020 | Dec 31, 2019 | $3.67B | Feb 3, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $2.36B | Feb 3, 2021 |
| FY2020 | Sep 30, 2020 | $2.93B | Feb 3, 2021 |
| FY2020 | Jun 30, 2020 | $3.27B | Feb 3, 2021 |
| FY2020 | Mar 31, 2020 | $3.08B | Feb 3, 2021 |
| FY2020 | Dec 31, 2019 | $3.22B | Feb 3, 2021 |
| FY2020 | Sep 30, 2019 | $3.17B | Feb 3, 2021 |
| FY2020 | Jun 30, 2019 | $3.14B | Feb 3, 2021 |
| FY2020 | Mar 31, 2019 | $2.89B | Feb 3, 2021 |
| FY2019 | Dec 31, 2018 | $3.04B | Feb 6, 2020 |
| FY2019 | Sep 30, 2018 | $2.98B | Feb 6, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.29B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $1.63B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $1.16B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $3.05B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $1.56B | Feb 14, 2024 |
| FY2020 | Dec 31, 2020 | $357.90M | Feb 3, 2021 |
| FY2020 | Sep 30, 2020 | $701.50M | Feb 3, 2021 |
| FY2020 | Jun 30, 2020 | $1.54B | Feb 3, 2021 |
| FY2020 | Mar 31, 2020 | $1.40B | Feb 3, 2021 |
| FY2020 | Dec 31, 2019 | $1.44B | Feb 3, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $2.84B | Feb 3, 2022 |
| FY2021 | Dec 31, 2020 | $4.55B | Feb 3, 2022 |
| FY2021 | Dec 31, 2019 | $7.04B | Feb 3, 2022 |
| FY2020 | Dec 31, 2018 | $5.89B | Feb 3, 2021 |
| FY2019 | Dec 31, 2017 | $5.35B | Feb 6, 2020 |
| FY2018 | Dec 31, 2016 | $5.15B | Feb 6, 2019 |
| FY2017 | Dec 31, 2015 | $4.89B | Feb 1, 2018 |
| FY2016 | Dec 31, 2014 | $3.97B | Feb 2, 2017 |
| FY2015 | Dec 31, 2013 | $2.52B | Feb 3, 2016 |
| FY2014 | Dec 31, 2012 | $1.86B | Feb 4, 2015 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $1.33B | Feb 5, 2013 |
| FY2012 | Dec 31, 2011 | $1.22B | Feb 5, 2013 |
| FY2012 | Dec 31, 2010 | $1.25B | Feb 5, 2013 |
| FY2009 | Dec 31, 2009 | $1.28B | Feb 9, 2010 |
| FY2009 | Dec 31, 2008 | $1.07B | Feb 9, 2010 |
| FY2009 | Dec 31, 2007 | $925.16M | Feb 9, 2010 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.43B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $2.40B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $2.55B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $2.40B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $2.67B | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $2.50B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $2.37B | Feb 3, 2022 |
| FY2020 | Dec 31, 2018 | $2.11B | Feb 3, 2021 |
| FY2019 | Dec 31, 2017 | $1.93B | Feb 6, 2020 |
| FY2018 | Dec 31, 2016 | $1.95B | Feb 6, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.20B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $2.88B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $1.55B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $1.38B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $3.64B | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $4.23B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $7.08B | Feb 3, 2022 |
| FY2020 | Dec 31, 2018 | $6.19B | Feb 3, 2021 |
| FY2019 | Dec 31, 2017 | $4.55B | Feb 6, 2020 |
| FY2018 | Dec 31, 2016 | $4.59B | Feb 6, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $153.80M | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $153.70M | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $277.00M | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $240.30M | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $258.10M | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $424.80M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $514.50M | Feb 3, 2022 |
| FY2020 | Dec 31, 2018 | $770.60M | Feb 3, 2021 |
| FY2019 | Dec 31, 2017 | $867.40M | Feb 6, 2020 |
| FY2018 | Dec 31, 2016 | $616.10M | Feb 6, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.44B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $28.05B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $26.84B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $24.55B | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | $23.88B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $24.62B | Feb 3, 2022 |
| FY2020 | Dec 31, 2019 | $27.23B | Feb 3, 2021 |
| FY2019 | Dec 31, 2018 | $25.29B | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $23.65B | Feb 6, 2019 |
| FY2017 | Dec 31, 2016 | $22.88B | Feb 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.18B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $11.33B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $12.05B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $11.17B | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | $12.92B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $13.93B | Feb 3, 2022 |
| FY2020 | Dec 31, 2019 | $13.90B | Feb 3, 2021 |
| FY2019 | Dec 31, 2018 | $12.26B | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $11.05B | Feb 6, 2019 |
| FY2017 | Dec 31, 2016 | $10.75B | Feb 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $14.80B | Feb 14, 2024 |
| FY2023 | Dec 31, 2022 | $13.40B | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | $10.90B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $10.70B | Feb 3, 2022 |
| FY2020 | Dec 31, 2019 | $13.34B | Feb 3, 2021 |
| FY2019 | Dec 31, 2018 | $13.04B | Feb 6, 2020 |
| FY2019 | Dec 31, 2017 | $12.61B | Feb 6, 2020 |
| FY2019 | Dec 31, 2016 | $12.14B | Feb 6, 2020 |
| FY2018 | Dec 31, 2015 | $9.37B | Feb 6, 2019 |
| FY2017 | Dec 31, 2014 | $10.81B | Feb 1, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.49B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $6.48B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $6.22B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $5.75B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $5.76B | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $5.76B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $5.76B | Feb 3, 2022 |
| FY2020 | Dec 31, 2018 | $5.71B | Feb 3, 2021 |
| FY2019 | Dec 31, 2017 | $4.63B | Feb 6, 2020 |
| FY2018 | Dec 31, 2016 | $3.67B | Feb 6, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.55B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $19.26B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $17.63B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $16.47B | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | $13.91B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $13.98B | Feb 3, 2022 |
| FY2020 | Dec 31, 2019 | $16.46B | Feb 3, 2021 |
| FY2019 | Dec 31, 2018 | $16.26B | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $15.81B | Feb 6, 2019 |
| FY2017 | Dec 31, 2016 | $15.07B | Feb 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $2.91B | Feb 6, 2020 |
| FY2019 | Dec 31, 2018 | $1.22B | Feb 6, 2020 |
| FY2019 | Dec 31, 2017 | $1.57B | Feb 6, 2020 |
| FY2019 | Dec 31, 2016 | $2.33B | Feb 6, 2020 |
| FY2018 | Dec 31, 2015 | $1.31B | Feb 6, 2019 |
| FY2017 | Dec 31, 2014 | $1.20B | Feb 1, 2018 |
| FY2016 | Dec 31, 2013 | $602.60M | Feb 2, 2017 |
| FY2015 | Dec 31, 2012 | $570.70M | Feb 3, 2016 |
| FY2014 | Dec 31, 2011 | $514.54M | Feb 4, 2015 |
| FY2013 | Dec 31, 2010 | $759.60M | Feb 6, 2014 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.29B | Feb 6, 2026 |
| FY2024 | Dec 31, 2024 | $6.30B | Feb 12, 2025 |
| FY2023 | Dec 31, 2023 | $6.94B | Feb 14, 2024 |
| FY2022 | Dec 31, 2022 | $6.28B | Feb 15, 2023 |
| FY2022 | Dec 31, 2021 | $6.27B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $7.43B | Feb 3, 2022 |
| FY2020 | Dec 31, 2019 | $4.46B | Feb 3, 2021 |
| FY2019 | Dec 31, 2018 | $5.94B | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $5.94B | Feb 6, 2019 |
| FY2017 | Dec 31, 2016 | $6.51B | Feb 1, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8 | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | 11 | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | 8 | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | 20 | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | 10 | Feb 14, 2024 |
| FY2020 | Dec 31, 2020 | 2 | Feb 3, 2021 |
| FY2020 | Sep 30, 2020 | 4 | Feb 3, 2021 |
| FY2020 | Jun 30, 2020 | 9 | Feb 3, 2021 |
| FY2020 | Mar 31, 2020 | 8 | Feb 3, 2021 |
| FY2020 | Dec 31, 2019 | 8 | Feb 3, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8 | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | 11 | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | 20 | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | 10 | Feb 14, 2024 |
| FY2020 | Dec 31, 2020 | 2 | Feb 3, 2021 |
| FY2020 | Sep 30, 2020 | 4 | Feb 3, 2021 |
| FY2020 | Jun 30, 2020 | 9 | Feb 3, 2021 |
| FY2020 | Mar 31, 2020 | 8 | Feb 3, 2021 |
| FY2020 | Dec 31, 2019 | 8 | Feb 3, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 146.80M | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | 145.80M | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | 144.90M | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | 144.00M | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | 147.00M | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | 152.40M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | 174.20M | Feb 3, 2022 |
| FY2020 | Dec 31, 2018 | 197.20M | Feb 3, 2021 |
| FY2019 | Dec 31, 2017 | 211.50M | Feb 6, 2020 |
| FY2018 | Dec 31, 2016 | 215.90M | Feb 6, 2019 |